Directorof Clinical Research
Obstetrics & Gynecology
Dr. Robert M. Wenham, MD
|
|
Give Review
Robert M. Wenham, MD works in the field of Obstetrics & Gynecology. He went to medical school at University of Texas Southwestern Medical School. He received awards:"Regional Top Doctor", "Super Doctor", "Fellow (FACS)" and "Fellow (FACOG)". Robert Wenham has written publications. He has 47 publications published with PubMed. The lastest paper is: 'Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.' Robert M. Wenham, MD accepts all Medicare patients.
Publications
- Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix.
- Micro-RNAs associated with the evolution of ovarian Cancer cisplatin resistance.
- Molecular determinants for lymph node metastasis in clinically early-stage endometrial Cancer.
- BAD-mediated apoptotic pathway is associated with human Cancer development.
- A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination With the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the ...
- The Chinese herb polyphyllin D sensitizes ovarian Cancer cells to cisplatin-induced growth arrest.
- A phase 1b study of trebananib in combination With pegylated liposomal doxorubicin or topotecan in women With recurrent platinum-resistant or partially platinum-sensit...
- A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced Cancer of the ovary, peritoneum, and fallopian tube.
- Human Cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.
- Gene expression data reveals common pathways that characterize the unifocal nature of ovarian Cancer.
- Perifosine, an AKT inhibitor, modulates ovarian Cancer cell line sensitivity to cisplatin-induced growth arrest.
- Lagged relationships among sleep disturbance, fatigue, and depressed mood during chemotherapy.
- A Phase II Trial of Docetaxel and Bevacizumab in Recurrent Ovarian Cancer within 12 Months of Prior Platinum-Based Chemotherapy.
- A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian Cancer cell growth.
- Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian Cancers.
- The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian Cancer.
- In vitro analysis of ovarian Cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.
- Implementing personalized medicine in a Cancer center.
- The BCL2 antagonist of cell death pathway influences endometrial Cancer cell sensitivity to cisplatin.
- BAD phosphorylation determines ovarian Cancer chemo-sensitivity and patient survival.
- Ovarian Cancer: a bright future.
- Genomic-directed targeted therapy increases endometrial Cancer cell sensitivity to doxorubicin.
- Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects With solid...
- Gedunin, a novel natural substance, inhibits ovarian Cancer cell proliferation.
- Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for Pelvic exenterations.
- Evaluation of the porcine model to teach various ancillary procedures to Gynecologic oncology fellows.
- MicroRNAs and their target messenger RNAs associated with ovarian Cancer response to chemotherapy.
- Ovarian adenoCarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
- The molecular biology of endometrial Cancers and the implications for pathogenesis, classification, and targeted therapies.
- Endometrial Cancer: contemporary insights into our most common gynecologic Cancer.
- Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis With bexarotene.
- MicroRNAs and their target messenger RNAs associated with Endometrial carcinogenesis.
- MicroRNA expression profiling in human ovarian Cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.
- Phase II study of bevacizumab in patients with platinum-resistant ovarian Cancer or peritoneal serous Cancer.
- Grade-specific prostate Cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites.
- Sexual health in women treated for Cervical cancer: characteristics and correlates.
- IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate Cancer in Black and White men.
- Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian Cancers.
- Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian Cancer.
- Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian Cancer.
- No relationship between ovarian Cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
- Molecular aspects of ovarian Cancer.
- Monsel's Solution: A Brief History.
- Can Monsel's Transmit Nosocomial Infections? A Microbiological Investigation.
- Stage IIB-IVB cervical adenoCarcinoma: prognostic factors and survival.
- Sensitivity of ovarian Cancer cells to acetaminophen reveals biological pathways that affect patient survival.
Schools
University of Texas Southwestern Medical Center At Dallas
Brigham and Womens Hospital and Massachusetts General Hospital
Duke University Medical Center
University Of North Texas
MsUniversity Of North Texas Health Science Center
Procedures Preformed
- Abdominal Hysterectomy With Robotic Assistance
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Destruction or Excision of Vaginal Lesions
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
- Accountable Health Plans of America
- Advantra
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Choice Care (Humana)
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access
- Group Plan PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
- Vista Health Plan
Awards
- Regional Top Doctor
- Super Doctor
- Fellow (FACS)
- Fellow (FACOG)
Education
-
Duke University Hospital -
Massachusetts General Hospital -
Brigham and Women's Hospital -
University of Texas Southwestern Medical School
Hospital
-
Duke University Hospital -
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1295740645 | |
| NPPES Provider LastName | WENHAM | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 143.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 10.49 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295740645 |
| Last Name Of The Provider | WENHAM |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Mitchel S. Hoffman, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Jesus Gonzalez Bosquet, MD |
|
Dr. Sachin M. Apte, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James P. Lapolla, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hye Sook Chon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robyn A. Sayer, MD |
|
Dr. Sandy B. Goodman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Spinnato, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. John H. Marston, MD
This Doctor is OpenDoctor Recommended.
|